ATS 2019 Virtual Final Program

1023 Effect of Opioid Use on Outcomes for Patients with Chronic Obstructive Pulmonary Disease (COPD): Who Pays the Price?/ A. Chakraborti, R. Ramanathan, J.J. Alunilkummannil, A. Menon, Brooklyn, NY, p.A7458 BEHAVIORAL • CLINICAL POSTER DISCUSSION SESSION D23 COPD: DIAGNOSIS AND EPIDEMIOLOGY 9:15 a.m. - 11:15 a.m. KBHCCD Room C141/C143/C149 (Level 1) Poster Viewing 9:15-10:00 Discussion 10:00-11:15 Chairing: N.A. Hanania, MD, MS, ATSF, Houston, TX A. Diaz, MD, Boston, MA 201 The Association Between Dementia and COPD: A Nationwide Population Based, Propensity Score Matched Cohort Study/ K.M. Liao, Tainan, Taiwan, p.A5940 202 Women with COPD Experience Increased Symptom Burden, Frequent and Severe Exacerbation, and Impaired Functional Capacity as compared to Men in SPIROMICS/ A. Lambert, B. Dieter, I. Barjaktarevic, R.G. Barr, S.P. Bhatt, S. Christenson, A.P. Comellas, C.B. Cooper, J.L. Curtis, M.B. Drummond, A. Fawzy, E.A. Hoffman, S. Hu, R.J. Kaner, R.E. Kanner, V. Kim, J.A. Krishnan, S.C. Lazarus, E.R. Neptune, E. Oelsner, E. Oelsner, V.E. Ortega, R. Paine, L.M. Paulin, C.S. Pirozzi, N. Putcha, M.B. Scholand, J.C. Sieren, D.P. Tashkin, J.M. Wells, M.-L. Wilgus, R.A. Wise, N.N. Hansel, M.K. Han, Spokane, WA, p.A5941 203 Impulse Oscillometry Indices Differentiate Non-Obstructed Smokers with and Without Respiratory Symptoms and Are Associated with Symptom Severity and Functional Exercise Capacity/ J.M. Bon, C. Riley, C. Karoleski, R. Wilson, W.A. Slivka, F.C. Sciurba, Pittsburgh, PA, p.A5942 204 Factors Influencing Decline in Quality of Life in Smokers: The COPDGene Study/ T. Parekh, S. Bhatia, A. Cherrington, Y.-I. Kim, A. Lambert, D.L. DeMeo, M.K. Han, M.T. Dransfield, Birmingham, AL, p.A5943 205 Disease Burden, Health Care Utilization, and Unmet Need Among Chronic Obstructive Pulmonary Disease (COPD) Patients in United Kingdom (UK) General Practice/ L. Sansbury, C. Bains, S. Ho, A. Ismaila, G. Anley, Collegeville, PA, p.A5944 206 Combined Effects of Lung Function, Blood Gases and Renal Function on Exacerbations in Stable COPD: Data from the Cosyconet Cohort/ F.C. Trudzinski, K. Kahnert, C. Vogelmeier, P. Alter, F. Seiler, S. Fändrich, H. Watz, T. Welte, T. Speer, D. Fliser, S. Zewinger, F. Biertz, H.-U. Kauczor, A. Koch, R. Jörres, R. Bals, Homburg, Germany, p.A5945 207 Common Respiratory Pathogens Other than Haemophilus in Small Airways Are Associated with Neutrophilic Inflammation and Poor Health Status in COPD: Results from the DISARM Study/ N.M. Alotaibi, F.S.S. Leitao Filho, J.-Y. Moon, H. Takiguchi, Y. Sun, S. Tam, S.F. Van Eeden, T. Shaipanich, S. Lam, J. Leung, D.D. Sin, Riyadh, Saudi Arabia, p.A5946 208 The Association Between Lung and Coronary Artery Disease in HIV/ D. Chandra, A. Gupta, M. Fitzpatrick, S. Haberlen, M. Neupane, J.K. Leader, L. Kingsley, E.C. Kleerup, M. Budoff, M. Witt, F.C. Sciurba, W. Post, A.M. Morris, Pittsburgh, PA, p.A5947 209 Cell-Derived Microparticles as Possible Markers of Severity in Chronic Obstructive Pulmonary Disease/ D. Nieri, M. Daniele, T. Neri, S. Lombardi, G. De Cusatis, M.A. Roggi, S. Santerini, B. Vagaggini, R. Vargiu, P.L. Paggiaro, A. Celi, Pisa, Italy, p.A5948 210 Ultrasound Evaluation of the Quadriceps Muscle in Patients with Chronic Obstructive Pulmonary Disease: Relationships with Clinical Symptoms, Disease Severity and Diaphragm Contractility/ A.-C. Maynard-Paquette, C. Poirier, B.P. Dubé, Montreal, Canada, p.A5949 211 Characterization of COPD Patients Experiencing Clinically Relevant Improvement Vs Worsening in Health Status 2 Years After a Change of Maintenance Treatment in the ‘Real-life’ Daccord Study/ P. Kardos, C.-P. Criée, K. Berschneider, V. Obermoser, C. Vogelmeier, R. Buhl, H. Worth, Frankfurt am Main, Germany, p.A5950 212 Prevalence and Associated Risk of Chronic Obstructive Pulmonary Disease in Heart Failure - A Decade (2007-2016) Analysis of the National Health and Nutrition Examination Survey (NHANES)/ T. Olanipekun, O. Oni, O. Oni, O. Bewaji, G.E. Westney, Atlanta, GA, p.A5951 213 Stability of Depressive Symptoms Experienced by Outpatients with Severe Chronic Obstructive Pulmonary Disease/ J. Hart, A. Summer, L. Ogunduyile, S.D. Halpern, Philadelphia, PA, p.A5952 214 Respiratory Symptoms in COPD Gene Subjects with the Alpha-1 Antitrypsin PI MZ Genotype/ X. Soler, S.P. Bhatt, A. Yen, J.W. Ramsdell, M.J. Strand, A. Diaz, R. San Jose Estepar, C.P. Hersh, R.P. Bowler, M.G. Foreman, A. Anzueto, J.D. Crapo, E.K. Silverman, M.K. Han, San Diego, CA, p.A5953 215 Association Between Low Peak Inspiratory Flow Rate (PIFR) and Inspiratory Muscle Strength as Measured by Hand Grip Strength in Hospitalized Patients with Acute Exacerbation of COPD/ A. Samarghandi, C. DeWilde, A. Priday, L. Puckett, D. Khorsandi, R. Qayyum, Richmond, VA, p.A5954 216 Five-Year Mortality of Chronic Obstructive Pulmonary Disease (COPD) Patients Is Greater than That of Asthmatics at Similar Airflow Obstruction/ C. Lin, H.-Y. Huang, C.-H. Wang, K.F. Chung, Taoyuan, Taiwan, p.A5955 217 Causes of Death in Japanese Patients with Chronic Obstructive Pulmonary Disease: Analysis from the Hokkaido COPD Cohort Study/ H. Makita, M. Suzuki, K. Shimizu, S. Konno, M. Nishimura, Sapporo, Japan, p.A5956 218 Burden of PiZ Heterozygosity for Alpha-1 Antitrypsin in the Population of Liver Transplant Recipients/ R. Cortes Lopez, D. Markovic, K. Melamed, T.S. Wang, V. Agopian, J. Dinorcia, F. Kaldas, G. Choi, I. Barjaktarevic, Los Angeles, CA, p.A5957 ATS 2019 • Dallas, TX 324 WEDNESDAY • MAY 22